Literature DB >> 12077043

Evaluating drug treatments for Parkinson's disease: how good are the trials?

Keith Wheatley1, Rebecca L Stowe, Carl E Clarke, Robert K Hills, Adrian C Williams, Richard Gray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12077043      PMCID： PMC1123447          DOI： 10.1136/bmj.324.7352.1508

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  18 in total

1.  The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.

Authors:  D Moher; K F Schulz; D G Altman
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.

Authors:  O Rascol; D J Brooks; A D Korczyn; P P De Deyn; C E Clarke; A E Lang
Journal:  N Engl J Med       Date:  2000-05-18       Impact factor: 91.245

3.  Medical management of Parkinson's disease.

Authors:  C E Clarke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-03       Impact factor: 10.154

Review 4.  Treatment interventions for Parkinson's disease: an evidence based assessment.

Authors:  Olivier Rascol; Christopher Goetz; William Koller; Werner Poewe; Cristina Sampaio
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 5.  Depression and Parkinson's disease: a review.

Authors:  J L Cummings
Journal:  Am J Psychiatry       Date:  1992-04       Impact factor: 18.112

6.  Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards.

Authors:  K Dickersin; Y I Min; C L Meinert
Journal:  JAMA       Date:  1992-01-15       Impact factor: 56.272

7.  Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.

Authors:  C Counsell
Journal:  BMJ       Date:  1998-12-05

Review 8.  Pramipexole for levodopa-induced complications in Parkinson's disease.

Authors:  E Clarke C; M Speller J; A Clarke J
Journal:  Cochrane Database Syst Rev       Date:  2000

9.  ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1995-03-18       Impact factor: 79.321

10.  The nighttime problems of Parkinson's disease.

Authors:  A J Lees; N A Blackburn; V L Campbell
Journal:  Clin Neuropharmacol       Date:  1988-12       Impact factor: 1.592
View more
  5 in total

1.  Funding evidence: the National Institute of Neurological Disorders and Stroke Clinical Trials Program.

Authors:  Bernard Ravina; Scott Janis; Julianna Keleti; John M Marler
Journal:  NeuroRx       Date:  2004-07

2.  Testing the SF-36 in Parkinson's disease. Implications for reporting rating scale data.

Authors:  P Hagell; A L Törnqvist; J Hobart
Journal:  J Neurol       Date:  2008-01-22       Impact factor: 4.849

Review 3.  Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease.

Authors:  David A Gallagher; Anette Schrag
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  The 39 item Parkinson's disease questionnaire (PDQ-39) revisited: implications for evidence based medicine.

Authors:  Peter Hagell; Carita Nygren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-18       Impact factor: 10.154

5.  Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective.

Authors:  David J Brooks
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.